2025-01-25 11:50:00 :
Supriya Life Sciences Q3 2025 Results: Supriya Life Sciences announced its third quarter results on January 24, 2025, revealing impressive financial results for the quarter. The company’s revenue increased by 32.54% year-on-year, and its profit increased by 57.03% year-on-year. The profit for the quarter was $467.8 Crores while revenue reached $185.65 Crore.
Despite strong year-over-year growth, the company faced challenges compared with the previous quarter, with revenue and profit falling 43.18% and 48.47% respectively. It is worth noting that selling, general and administrative expenses decreased by 50.29% month-on-month, but increased by 12.59% year-on-year.
Operating income also declined, down 48.25% month-on-month, but up 62.51% year-on-year. Third quarter earnings per share (EPS) reported at $5.82, an increase of 57.3% compared with the same period last year.
Supriya Life Sciences returned 9.47% last week and has returned a whopping 90.62% over the past six months, although it’s down slightly year-to-date at -1.28%.
As of January 25, 2025, Supriya Life Sciences had a market capitalization of $Rs 5,878.06 crore, a new 52-week high $835.2 and minimum $288.9. Analysts remain optimistic, with one in 10 giving the stock a “strong buy” rating.
As of January 25, 2025, the consensus recommendation was “Strong Buy,” indicating confidence in the company’s future performance and growth potential.
Supriya Life Sciences Finance
| period | Q3 (FY2025) | Q2 (FY25) | month-on-month growth | Q3 (FY2024) | year-on-year growth |
|---|---|---|---|---|---|
| total revenue | 185.65 | 326.73 | -43.18% | 140.07 | +32.54% |
| Total Selling/General/Administrative Expenses | 19.77 | 39.77 | -50.29% | 17.56 | +12.59% |
| Depreciation/Amortization | 4.96 | 9.4 | -47.23% | 3.96 | +25.25% |
| total operating expenses | 124.66 | 208.87 | -40.32% | 102.55 | +21.56% |
| operating income | 60.99 | 117.86 | -48.25% | 37.53 | +62.51% |
| net income before tax | 62.58 | 121.84 | -48.64% | 40.1 | +56.06% |
| net income | 46.78 | 90.79 | -48.47% | 29.79 | +57.03% |
| Diluted normalized earnings per share | 5.82 | 11.28 | -48.4% | 3.7 | +57.3% |
Disclaimer: This is an AI-generated live blog and has not been edited by LiveMint staff.
Follow us On Social Media Twitter/X